Lv4
500 积分 2026-06-15 加入
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1
5小时前
待确认
Myeloid Cells Induce Infiltration and Activation of B Cells and CD4+ T Follicular Helper Cells to Sensitize Brain Metastases to Combination Immunotherapy
5小时前
已完结
Nivolumab plus ipilimumab with chemotherapy for non–small cell lung cancer with untreated brain metastases: A multicenter single-arm phase 2 trial (NIke, LOGiK 2004)
5小时前
已完结
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1
5小时前
已完结
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study
5小时前
已完结
Nomogram Using CT Radiomics Features for Differentiation of Pneumonia-Type Invasive Mucinous Adenocarcinoma and Pneumonia: Multicenter Development and External Validation Study
1个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
1个月前
已完结
Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group–American College of Radiology Imaging Network E4512): a phase 3 trial
1个月前
已完结
Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002)
1个月前
已完结
Cell death crosstalk in NET-Driven inflammation: mechanisms, disease contexts, and therapeutic perspectives
1个月前
已完结
皖公网安备34019202002308
